



# Nexstim

## Targeting a paradigm shift in stroke rehabilitation

Martin Jamieson | CEO & Chairman of the Board | Nexstim

Corporate Presentation, AGM 28 March 2017

 @NexstimOyj

# Important information

This document and the information contained herein are being presented by Nexstim Oyj (“Nexstim” or the “Company”). In connection with any presentation or review of this document, you agree to be bound by the following limitations and notifications.

This document and the information contained herein are being provided to you solely for your information. The distribution of this document in some jurisdictions may be restricted by law and persons into whose possession this document comes are required to inform themselves about and observe any such restrictions. Accordingly, this document may not be distributed in any jurisdiction except under circumstances that will result in compliance with applicable laws and regulations.

This document is not a prospectus, and the information contained herein does not and is not intended to constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of any securities in connection with this document in any jurisdiction. This document and the information contained herein are not an offer of securities in the United States and are not for distribution in the United States.

Recipients should not treat the contents of the document as advice relating to legal, taxation or other matters. This presentation does not purport to be all-inclusive or to contain any or all the information that prospective investors may desire in analysing and deciding whether or not to hold or transact in the Company’s shares. Neither the Company nor any of its affiliates or representatives makes any representation or warranty, express or implied, as to the accuracy or completeness of this document or any of the information contained herein, or any other written or oral communication transmitted or made available to the recipient or its affiliates or representatives. The Company and its affiliates or representatives expressly disclaim to the fullest extent permitted by law any and all liability based, in whole or in part, on this document or any information contained herein or any other written or oral communication transmitted or made available to the recipient or its affiliates or representatives, including, without limitation, with respect to errors therein or omissions therefrom.

Recipients should not assume that the information in this document is accurate as of any date other than the date of this presentation. Nothing contained herein is, or should be relied upon as, a promise or representation as to future performance. The Company does not undertake any obligation to update or revise this this document.

Certain of the information contained herein concerning industry and market data, economic trends, market position and competitiveness is based upon or derived from information provided by third-party consultants and other industry sources. Neither the Company nor any of its affiliates or representatives can guarantee the accuracy of such information or has independently verified the assumptions upon which projections of future trends and performance in such information are based.

Nexstim's NBS System is cleared by the FDA for assessment of the motor and speech cortices for pre-procedural planning. The NBT System is not cleared for commercial distribution in the United States.

## **FORWARD-LOOKING STATEMENTS**

This document may contain forward-looking statements that reflect the Company’s current views with respect to certain future events and potential financial performance. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will materialise. Accordingly, results could differ materially from those set out in the forward-looking statements as a result of various factors. To the extent that this document contains opinions, estimates, forecasts or other forward looking statements, no guarantees or undertakings that these are correct or complete are given by the Company or any of its respective members, advisors, officers or employees or any other person. Forecasts and assumptions which are subject to economic and competitive uncertainty are outside such person’s control and no guarantee can be given that projected results will be achieved or that outcomes will correspond with forecasts. Information in this document may be changed, added to or corrected without advance notification.


# Nexstim Transcranial Magnetic Stimulation (TMS) platform

## Nexstim


Diagnostic

Therapy

Navigated Brain Stimulation (NBS)



Navigated Brain Therapy (NBT®)



# Platform protected with 17 patent families

- **63 granted patents, 35 pending**
- **Right to software:** Nexstim owns rights to its NBT<sup>®</sup> and NBS Systems' software developed in-house.
- **Core algorithms kept as trade secrets**



A network diagram on an orange background. It features a complex web of white lines connecting various nodes. Some nodes are represented by concentric circles, and others by solid blue dots. The connections are a mix of white and blue lines, creating a layered or highlighted network structure.

# Nexstim


**Navigated Brain Stimulation<sup>®</sup> for  
pre-surgical mapping of motor and  
speech cortex**



@NexstimOyj

# NBS Pre-Surgical Mapping makes the difference to clinical outcome

## Progression-free Survival (Months)




<sup>1</sup> Dietmar Frey, Peter Vajkoczy, and Thomas Picht **Navigated transcranial magnetic stimulation improves the treatment outcome in patients with brain tumors in motor eloquent locations** Neuro Oncology 2014 : nou110v1-nou110

# NBS Pre-Surgical Mapping Major Centers



# NBS Pre-Surgical Mapping US Distribution Partners








# Nexstim


## Navigated Brain Therapy<sup>®</sup>

# NBT<sup>®</sup> (Navigated Brain Therapy) has potential for multiple therapeutic applications due to precise navigation




# Market opportunity in stroke rehabilitation

2015 Incidence of stroke



2015 Stroke survivors




\*Published data

- Large and rapidly growing market
- 50% of stroke survivors will have upper limb paralysis with few available treatment options
- Focus on the period over 3 months post stroke

# Clinical data comparing NBT<sup>®</sup> + occupational therapy (OT) with OT


## Phase III NICHE results



Clinically meaningful response is >5points in UEFM score

- 199 patients – 12 leading US centres
- Excellent results in active group
- Sham coil in control group proved active
- Safety endorsed by DSMB

## Supplementary trial



Clinically meaningful response is >5points in UEFM score

- 60 patients – 5 leading US centres
- FDA approved trial protocol December 2016
- Study commenced February 2017 with expected completion by March 2018
- Active group data from Phase III and supplementary trial to be pooled

# Key performance indicators

EUR in thousands

	H2 2016 6 months	H2 2015 6 months	FY 2016 12 months	FY 2015 12 months	
Net sales	1,590.1	1,884.7	2,482.6	2,527.9	Full year expenses EUR 2,546.1 thousand lower related to Phase III multi-centre trial ending in H1 2016.
Personnel expenses	-2,038.7	-2,063.8	-4,253.2	-3,969.8	
Depreciation and amortisation	-203.5	-217.3	-372.3	-386.0	
Other operating expenses	-1,496.8	-4,420.3	-3,907.6	-7,843.0	Achieved H2 2016 targeted lower cash burn
Profit/ -Loss for the period	-2,506.2	-5,272.0	-6,732.7	-9,827.0	
Earnings per share (EUR)	-0.16	-0.73	-0.56	-1.37	
Cash flows from operating activities	-1,984.6	-4,333.3	-7,225.3	-9,608.6	Cash plus cash generated from sales, and the remaining financing arrangements with Bracknor and Sitra are now estimated to finance the Company until Q4 2018.
Cash in hand and at banks	8,156.4	6,874.7	8,156.3	6,874.7	
Total equity	4,478.5	3,545.1	4,478.5	3,545.1	
Equity ratio (%)	55.12	44.16	55.12	44.16	
Number of shares in the end of the period (pcs)	47,087,749	8,010,758	47,087,749	8,010,758	
Average number of shares during the period (pcs)	15,826,991	7,178,584	11,950,664	7,154,868	
Diluted number of shares in the end of the period (pcs)	78,830,446	8,797,698	78,830,446	8,797,698	
Diluted average number of shares during the period (pcs)	22,521,296	7,965,524	15,762,543	7,941,808	


# Nexstim Funding

- Accelerated pace in the two year funding arrangement with Bracknor Investment and Finnish Innovation Fund Sitra
- Funding arrangement is a combination of:
  - EUR 5 million of convertible bonds – 100% funded
  - EUR 6.5 million stand-by equity facilities ~92% funded
  - EUR 0.5 million direct share issue – 100% funded
  - EUR 15.0 million warrants – strike range EUR 0.14 - 0.85
- Open elements in the funding are the Sitra stand-by-equity facility of EUR 0.5 million and the EUR 15.0 million in warrants



# Nexstim Strategic Actions

- Focus on therapeutic applications – Primarily Stroke, Depression and Pain



# Nexstim Strategic Actions

## Timeline of US Regulatory Development for Stroke



Rehabilitation Institute of Chicago

**Rehabilitation Institute of Chicago (central site)**



Spaulding Rehabilitation Hospital (Boston)



Rancho Los Amigos National Rehabilitation Center



Burke Rehabilitation Hospital (White Plains, NY)



University of Cincinnati



# Nexstim Strategic Actions

- File 510(k) for depression during H1 2017
- Exploit CE marked approval in Stroke – EU sales to begin in H1 2017
- Partner agreements to include major Asian territories
- Prepare funding plan for US therapy commercialisation





# Nexstim

Thank you